Radiotherapy to treat remaining spread in metastatic prostate cancer
Tests targeted radiotherapy added to hormone-sensitive metastatic prostate cancer treatment.
Plain-language title generated from the registry record
Registry title: Radiotherapy to Consolidate Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)
Key facts
- Where
- Montreal, CanadaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with hormone-sensitive prostate cancer that has spread. Their cancer has responded to drug treatment, and their PSA is not rising.
- Sex
- Men only.
- Disease stage
- Hormone-sensitive metastatic prostate cancer that has responded to systemic therapy, with PSA not progressing. The spread must be treatable with metastasis-directed radiotherapy (MDRT).
- Earlier treatment
- Must have started systemic therapy and responded to it. The primary tumor must have had definitive local treatment (surgery or radiotherapy) with no sign of local recurrence, or be planned for treatment at the time of MDRT.
- Biomarker or test result
- PSA must not be progressing.
Main reasons for not taking part
- Planned intermittent systemic therapy
- Planned radio-ligand therapy
- ECOG score higher than 2
Read by machine on 12 November 2026.
Where in Canada
- CRCHUMMontreal, CanadaContact: Mom PhatTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Centre hospitalier de l'Université de Montréal (CHUM)
- Trial code
- NCT05457699
- Record updated
- 8 September 2026
- Original description
This will be a pragmatic, phase II, registry-based cohort-multiple randomized controlled trial (cmRCT) embedded within an ongoing prospective cancer radiotherapy registry. Eligible patients are those with hormone-sensitive metastatic prostate cancer who have responded to systemic therapy, defined by the absence of PSA progression, and who are eligible for MDRT. All eligible subjects will be enrolled into the registry and followed longitudinally for oncologic and toxicity outcomes.Read full original descriptionShow less
Radiotherapy to Consolidate Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)
This will be a pragmatic, phase II, registry-based cohort-multiple randomized controlled trial (cmRCT) embedded within an ongoing prospective cancer radiotherapy registry. Eligible patients are those with hormone-sensitive metastatic prostate cancer who have responded to systemic therapy, defined by the absence of PSA progression, and who are eligible for MDRT. All eligible subjects will be enrolled into the registry and followed longitudinally for oncologic and toxicity outcomes.
From this registry, patients will be randomly selected (1:1) to be offered the experimental arm, which consists of MDRT delivered to metastatic sites identified on imaging in patients who have already initiated systemic therapy (Figure 1). Those not selected will continue to receive standard of care systemic therapy +/- standard of care radiotherapy if clinically indicated. Nor patients or physicians will be blinded.
Following the initial course of MDRT, prostate-specific antigen (PSA) will be measured, with a minimum assessment at 3 months. This PSA value will be used to determine whether the PSA level has decreased below 0.2 ng/mL. If the PSA remains ≥ 0.2 ng/mL, repeat PSMA-PET will be performed, and a second course of MDRT will be delivered to consolidate residual metastatic lesions.
In this phase II real-world randomized trial, we will determine if AnChoRing (Addition of MDRT for consolidation of response) sites of PSMA PET visible disease when responding to systemic therapy improves the proportion of patients achieving a PSA < 0.2 ng/mL and extends failure-free survival compared to the standard of care.
Inclusion: Enrolled in PERa (CHUM CER 17.032) and randomly selected for ANCHOR-Prostate; Diagnosis of hormone-sensitive metastatic prostate cancer having responded to systemic therapy; PSA non-progressing; ECOG 0-2; Metastatic disease suitable for MDRT; Primary tumor must have received definitive local treatment (surgery or radiotherapy) with no evidence of local recurrence, or be planned for treatment at the time of MDRT.
Exclusion: Planned intermittent systemic therapy; Planned radio-ligand therapy.